Chemical Works of Gedeon Richter's quarterly market cap
increased
from Mar. 2025 ($4,956 Mil) to Jun. 2025 ($4,969 Mil) and
increased
from Jun. 2025 ($4,969 Mil) to Dec. 2025 ($5,654 Mil).
Chemical Works of Gedeon Richter's annual market cap
increased
from Dec. 2023 ($4,542 Mil) to Dec. 2024 ($4,956 Mil) and
increased
from Dec. 2024 ($4,956 Mil) to Dec. 2025 ($5,654 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Chemical Works of Gedeon Richter's Enterprise Value for Today is $6,402 Mil.
Chemical Works of Gedeon Richter (OTCPK:RGEDF) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Chemical Works of Gedeon Richter Market Cap Related Terms
Chemical Works of Gedeon Richter Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Chemical Works of Gedeon Richter's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chemical Works of Gedeon Richter Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Chemical Works of Gedeon Richter's Market Cap distribution charts can be found below:
* The bar in red indicates where Chemical Works of Gedeon Richter's Market Cap falls into.
Chemical Works of Gedeon Richter Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chemical Works of Gedeon Richter (RGEDF) has a Market Cap of $7,134 Mil as of Jun. 27, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Chemical Works of Gedeon Richter and its competitors. According to the industry distribution chart, Chemical Works of Gedeon Richter ranks #61 out of 1023 companies in the Drug Manufacturers industry, placing it in the top 6%.
Is Chemical Works of Gedeon Richter's Market Cap too high?
Chemical Works of Gedeon Richter's current Market Cap is $7,134 Mil. The Drug Manufacturers industry median Market Cap is 205.37. Chemical Works of Gedeon Richter's value of $7,134 Mil is 3373.7% above this industry median. Based on the distribution chart, Chemical Works of Gedeon Richter ranks #61 out of 1023 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Chemical Works of Gedeon Richter has a GF Score™ of 94/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Chemical Works of Gedeon Richter's Market Cap compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Chemical Works of Gedeon Richter ranks #61 out of 1023 companies for Market Cap. This places Chemical Works of Gedeon Richter in the top 6% of its industry — outperforming the majority of peers. The industry median Market Cap is 205.37. Chemical Works of Gedeon Richter's value of $7,134 Mil is 3373.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 205.37, based on 1,023 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chemical Works of Gedeon Richter's current Market Cap of $7,134 Mil is 3373.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Chemical Works of Gedeon Richter and its competitors. For the Drug Manufacturers industry, the median Market Cap is 205.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chemical Works of Gedeon Richter's current Market Cap is $7,134 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chemical Works of Gedeon Richter stock overvalued right now?
Based on GuruFocus' analysis, Chemical Works of Gedeon Richter (RGEDF) is currently considered Modestly Overvalued. The stock's GF Value™ is $35.22, compared to a current price of $39.59 — trading 12.4% above its estimated fair value. The current Market Cap is $7,134 Mil and 3373.7% above the Drug Manufacturers industry median of 205.37. Chemical Works of Gedeon Richter's overall GF Score™ is 94/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Chemical Works of Gedeon Richter (RGEDF), the current Market Cap is $7,134 Mil as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chemical Works of Gedeon Richter (RGEDF) Overvalued in 2026?
Based on GuruFocus' analysis, Chemical Works of Gedeon Richter stock appears to be overvalued.
The current stock price of $39.59 is trading 12.4% above its estimated GF Value™ of $35.22.
GuruFocus considers Chemical Works of Gedeon Richter to be Modestly Overvalued.
Key valuation signals for RGEDF:
Market Cap: $7,134 Mil
GF Value™: $35.22 vs. price of $39.59 (12.4% above fair value)
Industry Position: 3373.7% above the Drug Manufacturers median (#61 of 1023)
No single metric tells the full story. See the RGEDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chemical Works of Gedeon Richter Business Description
Chemical Works of Gedeon Richter PLC is a pharmaceutical company. The company focuses on the development and manufacture of gynaecological, cardiovascular, and central nervous system products. It manufactures medicines including original, generic and licensed products for treatment in the therapeutic area. The group is active in two business segments namely, the Pharma segment comprising Women's Healthcare, Neuropsychiatry, Biotechnology, General Medicine, and Other pharma; and the Others segment includes the remaining wholesale and retail business of the Group and all other activities. The company operates internationally.
94GF Score
Get the complete analysis for RGEDF
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGEDF has been successfully added to your 
